Shanghai Cell Therapy Group Files for Hong Kong IPO as Leader in Immune Cell Storage Market

May 15, 2024 09:02 CST Updated 09:02

Shanghai Cell Therapy Group

Cell Health Medical Products and Service Provider

With Views, With Attitude

This is the Life Science Industry Observer Official Account's Issue #1010-4Article of the Term

Source: Fat Cell Notes

April 30, 2024,Shanghai Cell Therapy Group Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange as the first and only company in China covering the entire value chain of cell healthcare.

According to the prospectus and data from CIC Consulting, Shanghai Cell Therapy Group is the leader in China's immune cell storage business, ranking first in China. Specifically, in terms of the incremental number of immune cell storage units for each year from 2021 to 2023, as well as the cumulative number of stored immune cell units as of December 31, 2021, 2022, and 2023, the company ranked first in China's immune cell storage market.

Comparison: Various Cell Storage Data of Shanghai Cell Therapy Group and Listed Company Zhongyuan Xiehe:

(FromShanghai Cell Therapy Group Prospectus）

(From the 2023 Annual Report of Zhongyuan Union)Notice)

In terms of umbilical cord blood hematopoietic stem cell storage, Zhongyuan Union is one of the seven earlier licensed cord blood banks (the seven cord blood banks are respectively Beijing, Tianjin, Shandong, Shanghai, Guangdong, Sichuan, and Zhejiang), leading toInTotal Amount of Stem Cell StorageShanghai Cell Therapy Group is only about 40% of Zhongyuan Xiehe, but it isTotal Amount of Immune Cell StorageApproximately 120 times that of the latter。

Such data is attributed to their well-established channel layout:

a. Cell Storage Service Network

（From the prospectus of Shanghai Cell Therapy Group）

b. Proportion of Channel and Institutional Collaboration

(From the prospectus of Shanghai Cell Therapy Group)

Of course, Shanghai Cell Therapy Group is committed to becoming a company that covers the entire value chain of cell medical health. Its business scope not only includes cell storage but also covers tumor treatment, cell drugs, and cell recharging.。Comprehensively utilizing its proprietary technology platforms, such as the nanobody-based cell navigation and control platform, the non-viral gene writing platform, and the nucleic acid synthesis and delivery platform, along with the support of comprehensive core service infrastructures including cell repositories, cell factories, oncology hospitals, and medical testing laboratories, to provide customers withProviding all-round, one-stop cell-based medical and health products and services, successfully building a closed-loop cell-based medical and health ecosystem with strong synergy.

（From the prospectus of Shanghai Cell Therapy Group）

In conclusion, with the release of this IPO filing:

a. Believe that many companies have already paid attention, especiallyYesImmune Cell Storage Section(There are quite a few non-cellular listed companies that are even preparing to launch similar businesses).

b. It is estimated that the headhunting action plan surrounding channel personnel has been placed on the desks of various bosses.

c. There is another wave of construction boom for immune cell storage facilities (equipment, reagents, consumables, etc.)

Are you ready?

---The End---

Welcome to follow the official account by clicking.

If you like it, just one-click triple action: like, favorite, and share.！